
KMTS Stock Forecast & Price Target
KMTS Analyst Ratings
Bulls say
Kestra Medical Techs is a commercial-stage medical device and digital healthcare company with a promising product portfolio that targets cardiovascular disease. The company has shown strong progress through consistent improvement in conversion rate drivers, and has gained market share as well as expanded its reach to new prescribers. With a growing salesforce, ongoing product updates, and strategic collaborations, Kestra is well-positioned for potential durable revenue acceleration and gross margin expansion. While risks include commercial challenges and regulatory decisions, the company's solid financial profile and potential for further market share growth make it a favorable investment opportunity.
Bears say
Kestra Medical Techs is a commercial-stage MedTech company that has developed the ASSURE Cardiac Recovery System, including the wearable ASSURE WCD, which has received FDA PMA approval and has been commercially available since August 2022. Despite recent improvements in field team expansion and prescription trends, the company still faces challenges in driving conversion rate and reaching full productivity of new reps. Additionally, while there have been steady margin expansions, it remains unclear when the company will reach 70%+ margins or how the updates to the new algorithm will be implemented on all existing systems.
This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
KMTS Analyst Forecast & Price Prediction
Start investing in KMTS
Order type
Buy in
Order amount
Est. shares
0 shares